These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 17605973)

  • 1. Role of lipoprotein-associated phospholipase A2 in predicting risk of cardiovascular disease.
    Myerson M
    Mayo Clin Proc; 2007 Jul; 82(7):888; author reply 888-9. PubMed ID: 17605973
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipoprotein-associated phospholipase A2 and risk of stroke.
    Gorelick PB
    Am J Cardiol; 2008 Jun; 101(12A):34F-40F. PubMed ID: 18549870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
    Corson MA; Jones PH; Davidson MH
    Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lipoprotein-associated phospholipase A(2) and stroke].
    Alvarez-Pérez FJ; Verde I
    Rev Neurol; 2009 Jul 16-31; 49(2):88-94. PubMed ID: 19598138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
    Persson M; Hedblad B; Nelson JJ; Berglund G
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1411-6. PubMed ID: 17431184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein-associated phospholipase A2 and cardiovascular risk: state of the evidence and future directions.
    Iribarren C
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):5-6. PubMed ID: 16373620
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipoprotein-associated phospholipase A2 and risk stratification for cardiovascular disease: not ready for "prime time".
    Steinberg DI; Mayer A
    Mayo Clin Proc; 2007 Feb; 82(2):155-7. PubMed ID: 17290719
    [No Abstract]   [Full Text] [Related]  

  • 8. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.
    Tsimikas S; Tsironis LD; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2094-9. PubMed ID: 17626905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
    Davidson MH; Corson MA; Alberts MJ; Anderson JL; Gorelick PB; Jones PH; Lerman A; McConnell JP; Weintraub HS
    Am J Cardiol; 2008 Jun; 101(12A):51F-57F. PubMed ID: 18549872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lp-PLA₂- a novel risk factor for high-risk coronary and carotid artery disease.
    Epps KC; Wilensky RL
    J Intern Med; 2011 Jan; 269(1):94-106. PubMed ID: 21054587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
    Carlquist JF; Muhlestein JB; Anderson JL
    Expert Rev Mol Diagn; 2007 Sep; 7(5):511-7. PubMed ID: 17892360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
    Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein-associated phospholipase A2.
    McConnell JP; Hoefner DM
    Clin Lab Med; 2006 Sep; 26(3):679-97, vii. PubMed ID: 16938590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk.
    Greenland P; O'Malley PG
    Arch Intern Med; 2005 Nov; 165(21):2454-6. PubMed ID: 16314539
    [No Abstract]   [Full Text] [Related]  

  • 16. Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction.
    Cojocaru IM; Cojocaru M; Tănăsescu R; Iliescu I; Dumitrescu L; Burcin C; Gurban CV; Sfrijan F
    Rom J Intern Med; 2009; 47(1):61-5. PubMed ID: 19886071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.
    Khakpour H; Frishman WH
    Cardiol Rev; 2009; 17(5):222-9. PubMed ID: 19690473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor?
    Lerman A; McConnell JP
    Am J Cardiol; 2008 Jun; 101(12A):11F-22F. PubMed ID: 18549867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker.
    Toth PP; McCullough PA; Wegner MS; Colley KJ
    Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):425-38. PubMed ID: 20222820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.